Drug Patents owned by Eisai Inc

1. List of Aricept drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8481565 EISAI INC Method for stabilizing anti-dementia drug
Oct, 2026

(3 years from now)

Drugs and Companies using DONEPEZIL HYDROCHLORIDE ingredient

Market Authorisation Date: 23 July, 2010

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of ARICEPT before it's patent expiration?
More Information on Dosage

2. List of Banzel drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6740669 EISAI INC Crystal modification of 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide and its use as antiepileptic
Nov, 2022

(2 months ago)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6740669

(Pediatric)

EISAI INC Crystal modification of 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide and its use as antiepileptic
May, 2023

(3 months from now)

Drugs and Companies using RUFINAMIDE ingredient

Market Authorisation Date: 14 November, 2008

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of BANZEL before it's patent expiration?
More Information on Dosage

3. List of Dayvigo drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8268848 EISAI INC Cyclopropane compound
Sep, 2031

(8 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10188652 EISAI INC Compositions and methods for treating insomnia
Oct, 2035

(12 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Apr 7, 2025

Drugs and Companies using LEMBOREXANT ingredient

NCE-1 date: April, 2024

Market Authorisation Date: 07 April, 2020

Treatment: Treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance

Dosage: TABLET;ORAL

More Information on Dosage

4. List of Fycompa drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6949571 EISAI INC 1,2-dihydropyridine compounds, process for preparation of the same and use thereof
Jun, 2023

(4 months from now)

US8772497 EISAI INC Method for producing 1, 2-dihydropyridine-2-one compound
Jul, 2026

(3 years from now)

Drugs and Companies using PERAMPANEL ingredient

Market Authorisation Date: 22 October, 2012

Treatment: Treatment of partial-onset seizures with or without secondarily generalized seizures in patients with epilepsy 4 years of age and older; Treatment of partial-onset seizures with or without secondarily generalized seizures in patients with epilepsy; Treatment of primary generalized tonic-clonic seizures as adjunctive therapy in patients with epilepsy; Treatment of epilepsy; Treatment of primary generalized tonic-clonic seizures as adjunctive therapy in patients with epilepsy 12 years of age and older

Dosage: TABLET;ORAL

How can I launch a generic of FYCOMPA before it's patent expiration?
More Information on Dosage

5. List of Halaven drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6214865 EISAI INC Macrocyclic analogs and methods of their use and preparation
Jul, 2023

(5 months from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6214865

(Pediatric)

EISAI INC Macrocyclic analogs and methods of their use and preparation
Jan, 2024

(11 months from now)

USRE46965 EISAI INC Intermediates for the preparation of analogs of Halichondrin B
Jan, 2027

(3 years from now)

USRE46965

(Pediatric)

EISAI INC Intermediates for the preparation of analogs of Halichondrin B
Jul, 2027

(4 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Jan 28, 2023
M Sep 13, 2025
Pediatric Exclusivity (PED) Mar 13, 2026

Drugs and Companies using ERIBULIN MESYLATE ingredient

Market Authorisation Date: 15 November, 2010

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

How can I launch a generic of HALAVEN before it's patent expiration?
More Information on Dosage

6. List of Lenvima drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7253286 EISAI INC Nitrogen-containing aromatic derivatives
Oct, 2025

(2 years from now)

US7612208 EISAI INC Crystalline form of the salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide or the solvate of the salt and a process for preparing the same
Sep, 2026

(3 years from now)

US11186547 EISAI INC High-purity quinoline derivative and method for manufacturing same
Aug, 2035

(12 years from now)

US10259791 EISAI INC High-purity quinoline derivative and method for manufacturing same
Aug, 2035

(12 years from now)

US10407393 EISAI INC High-purity quinoline derivative and method for manufacturing same
Aug, 2035

(12 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9006256 EISAI INC Antitumor agent for thyroid cancer
Jul, 2027

(4 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Aug 15, 2025
New Indication (I) Aug 10, 2024
M Dec 19, 2024

Drugs and Companies using LENVATINIB MESYLATE ingredient

Market Authorisation Date: 13 February, 2015

Treatment: Method for treating thyroid carcinoma including differentiated thyroid cancer

Dosage: CAPSULE;ORAL

How can I launch a generic of LENVIMA before it's patent expiration?
More Information on Dosage

7. List of Lusedra drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6204257 EISAI INC Water soluble prodrugs of hindered alcohols
Jul, 2022

(7 months ago)

Drugs and Companies using FOSPROPOFOL DISODIUM ingredient

Market Authorisation Date: 12 December, 2008

Treatment: Sedative-hypnotic agent indicated for monitored anesthesia care (mac) sedation

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in